(ShareCast News) - Juno Therapeutics was set to surge at the open on Monday after agreeing for Celgene to buy the shares in the biopharmaceutical group it does not already own for around $9bn in cash. Under the terms of the deal, …
As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. Article printed from InvestorPlace Media, https://investorplace.com/2017/12/2018-better-celgene
Celgene turned in a brutal third-quarter earnings report, missing revenue forecasts and cutting its long-term profit outlook. Traders were woefully unhedged by several measures, leaving them vulnerable to feel the brunt of the stock's 20% drop. …
When investors are looking for high growth and reasonable valuations in the biotech space, Celgene Corporation (NASDAQ:CELG) is one of the first companies to come to mind. However, October was not kind to the CELG stock
Celgene (NASDAQ: CELG) stock has been in my investment portfolio since 2013. I enjoyed a couple of great years with the biotech stock performing really well. Over the past couple of years, however, Celgene hasn't generated high …
Even some of the biggest and best have things go wrong every now and then. Celgene (NASDAQ: CELG) has been the best-performing biotech stock over the last five years among big biotechs with market caps over $50 billion. And now, …
Celgene, a major biotech company, said on Thursday that it planned to stop developing a critical drug. The drug, …
Celgene (NASDAQ: CELG) has long garnered one of the richest valuations among large-cap biotechs, and for good reason. The long and short of it is that Celgene has been able to post industry-leading levels of revenue growth year …
Over the past five years, Celgene (NASDAQ: CELG) stock has soared 280%. That's better than any other biotech with a market cap of $50 billion or more. Celgene's past success stemmed primarily from four drugs: Revlimid, Pomalyst, …
To say 2017 was a tough year for Celgene Corporation (NASDAQ:CELG) and CELG stock would be a considerable understatement. Despite starting the year on the right foot and advancing 22% as of late September, bad R&D news …